Effects of CDK7 inhibition on fibrotic gene expression
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × DMSO vs 3 × THZ1 vs 3 × TGFb vs 3 × TGFb_THZ1Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting CDK7/12/13 functional synergism reverses myofibroblast activation and ameliorates lung fibrosisiScience · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE277437_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1162425 and SRA study SRP533317. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8522439 DMSO_4172 DMSO
- GSM8522440 DMSO_4173 DMSO
- GSM8522441 DMSO_4174 DMSO
- GSM8522442 THZ1_4175 THZ1
- GSM8522443 THZ1_4176 THZ1
- GSM8522444 THZ1_4177 THZ1
- GSM8522445 TGFb_4181 TGFb
- GSM8522446 TGFb_4182 TGFb
- GSM8522447 TGFb_4183 TGFb
- GSM8522448 TGFb_THZ1_4184 TGFb_THZ1
- GSM8522449 TGFb_THZ1_4185 TGFb_THZ1
- GSM8522450 TGFb_THZ1_4186 TGFb_THZ1
- GSE279730 Gene expression analysis of prostate cancer cells resistant to CDK7 inhibitors 12 samples shares cdk7
- GSE277035 Pre-clinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms (MPN) transformed to AML 10 samples shares cdk7
- GSE218269 CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release 100 samples shares cdk7
- GSE298581 Global gene expression response to PPARG inhibition in three urothelial cancer cell lines 48 samples shares inhibition
- GSE285406 ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer 48 samples shares cdk7
- GSE228346 The TFIIH kinase CDK7 governs RNA polymerase II initiation, elongation, termination, and RNA processing 30 samples shares cdk7
- GSE237951 Inhibition of EZH2 restores normal expression of genes associated with cysteine metabolism and ferroptosis in hepatocellular carcinoma [RNA-seq] 8 samples shares inhibition
- GSE254732 Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects 215 samples shares inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.